Literature DB >> 96188

Pathogenesis of Pseudomonas aeruginosa pneumonia during immunosuppression.

J E Pennington, M G Ehrie.   

Abstract

A guinea pig model of immunosuppression was utilized to study the effects of immunosuppressive chemotherapy on lung response to challenge with Pseudomonas aeruginosa. Study groups included normal guinea pigs, as well as guinea pigs that received a one-week course of cortisone acetate (CA, 100 mg/kg per day) plus 15 mg of cyclophosphamide (CTX)/kg per day (CA + LoCTX group) or 30 mg of cyclophosphamide/kg per day (CA + HiCTX group). Separate groups received CA or HiCTX alone. Intratracheal instillation of P. aeruginosa resulted in bilateral hemorrhagic pneumonia in both normal and immunosuppressed animals. Survival was 100% for normal animals and for those given CA alone, 67% in the CA + LoCTX and the HiCTX groups, and 0 in the CA + HiCTX group. Increased mortality correlated with a diminished polymorphonuclear leukocyte inflammatory response in infected lung tissues and also with the addition of CA to CTX. Clearance of viable P. aeruginosa from lung tissue was significantly reduced in animals receiving the combination CA + HiCTX. Thus, decreased lung inflammation and the addition of CA appeared to be important determinants for fatal pseudomonas pneumonia.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 96188     DOI: 10.1093/infdis/137.6.764

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  Isolation and partial characterization of a human alveolar macrophage-derived neutrophil-activating factor.

Authors:  J E Pennington; T H Rossing; L W Boerth; T H Lee
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

2.  Pseudomonas aeruginosa clearance in mice: comparison of tissue, strain, and corticosteroid effects.

Authors:  K M Nugent; C D Cox; E L Pesanti
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

3.  Innate immune properties of the immortalized macrophage cell line I-9.5.

Authors:  W Chang; S H Yeh; D B Drath
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-01       Impact factor: 2.416

4.  Pseudomonas aeruginosa exoproteases inhibit human neutrophil chemiluminescence.

Authors:  A Kharazmi; N Høiby; G Döring; N H Valerius
Journal:  Infect Immun       Date:  1984-06       Impact factor: 3.441

5.  Chronic glucocorticosteroid therapy impairs staphylococcal clearance from murine lungs.

Authors:  K M Nugent; E L Pesanti
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

6.  Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs.

Authors:  A Saito; K Sawatari; Y Fukuda; M Nagasawa; H Koga; A Tomonaga; H Nakazato; K Fujita; Y Shigeno; Y Suzuyama
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

7.  Prediction and diagnosis of early Pseudomonas aeruginosa infection in cystic fibrosis: a follow-up study.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

8.  Effector mechanisms of intestinally induced immunity to Pseudomonas aeruginosa in the rat lung: role of neutrophils and leukotriene B4.

Authors:  A Buret; M Dunkley; R L Clancy; A W Cripps
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

9.  Apoptosis inhibition in P. aeruginosa-induced lung injury influences lung fluid balance.

Authors:  Rozenn Le Berre; Karine Faure; Harold Fauvel; Nathalie B Viget; Florence Ader; Thierry Prangère; Anne Marie Thomas; Xavier Leroy; Jean-François Pittet; Philippe Marchetti; Benoit P Guery
Journal:  Intensive Care Med       Date:  2004-02-26       Impact factor: 17.440

10.  Effect of infectious dose and season on development of hemorrhagic pneumonia in mink caused by Pseudomonas aeruginosa.

Authors:  Charlotte Mark Salomonsen; Mariann Chriél; Trine H Jensen; Lena Rangstrup-Christensen; Niels Høiby; Anne Sofie Hammer
Journal:  Can J Vet Res       Date:  2013-07       Impact factor: 1.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.